BioPharmSignal logoBioPharmSignal

Biotech News

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics (CNTX)Context TherapeuticsCompany update

PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option

Related news

CNTXContext Therapeutics2026-07-10 20:05 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

FATEFate Therapeutics2026-08-03 20:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-08-18 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ERASErasca2026-08-10 20:01 EST

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-08-07 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-07-31 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

View all latest news

Context Therapeutics

Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a...

Recent company news

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

CNTXContext Therapeutics2026-07-10 20:05 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CNTXContext Therapeutics2026-07-06 20:07 EST

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

CNTXContext Therapeutics2026-06-15 10:30 EST

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

CNTXContext Therapeutics2026-06-09 20:10 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
0.50 USD
Market cap
222.35M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States